SurroMed And Ingenuity Systems Announce Partnership To Speed Biomarker Discovery In Clinical Research Studies


Mountain View, California, December 8, 2003 – SurroMed and Ingenuity announced today that SurroMed has licensed IPA, a web-delivered application that enables biologists to discover, visualize and explore therapeutically relevant networks significant to their experimental results. SurroMed collaborators and customers will now be able to quickly analyze the biology of their SurroMed mass spectrometry-based experiments for differential analysis and broad profiling of proteins and low-molecular-weight molecules using IPA.

The combination of the IPA application with SurroMed’s proprietary technologies for biomarker discovery in clinical research studies allows SurroMed’s collaborators and customers to more quickly and comprehensively understand drug mechanisms, discover root causes of disease, and discern the molecular basis of patient-to-patient variations in disease presentation, progression and response to treatment.

“Ingenuity’s technologies uniquely utilize a systems biology approach to analyzing proteomic and metabolomic datasets, resulting in both faster and more comprehensive analysis of experimental results,” stated Keith Joho, Vice President, Informatics and Bioanalytical Operations of SurroMed. “Using IPA, SurroMed’s collaborators and customers are now able to arrive at the biological relevance of their biomarker discovery experiments in a fraction of the time.”

“We are delighted to welcome SurroMed, a pioneer in biomarker enabled drug discovery and development, to our growing list of distinguished partners,” stated Frank C. Mara, senior vice president of Ingenuity Systems. “Both of our companies are dedicated to improving our customers. drug discovery productivity through the application of innovative technologies.”

IPA is available for a free trial to qualified research scientists at, or by contacting Peter DiLaura, Head of Corporate Development at 650.967.7777, ext 299.

About Ingenuity Systems

Ingenuity Systems is helping life science researchers explore and understand biological systems that are foundational to human health and disease. Ingenuity delivers capabilities and expertise to researchers through analysis software, genome-scale computable network databases, and knowledge management services and infrastructure, resulting in increased productivity and faster drugs to market. The company was founded in 1998 and is headquartered in Mountain View,

About SurroMed

Headquartered in Mountain View, California, SurroMed is pioneering biomarker enabled drug discovery and development. The company focuses on discovering and applying biomarkers to improve the drug discovery and development process and enable the precise diagnosis and personalized treatment of disease. SurroMed’s research process yields biological markers and information that enable accelerated, cost-efficient discovery and development of new therapeutic products, as well as development of diagnostic tests for early disease detection, disease staging, patient stratification, and guiding and monitoring therapy.